

Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement

<https://marketpublishers.com/r/OFE6925F280EN.html>

Date: November 2011

Pages: 6

Price: US\$ 90.00 (Single User License)

ID: OFE6925F280EN

Abstracts

Recent news about “possible acquisition of Onyx pharma” is not a surprise in light of the upcoming verdict on Carfilzomib’s (PhIIb, next-generation proteasome inhibitor, Relapsed and Refractory Multiple Myeloma – R/R MM) and recent settlement over Regorafenib (BAY73-4506, PhIII) with Bayer. Onyx product pipeline focuses only in oncology. We have prepared a matrix of key players in oncology by indications and also rank order the suitors based on their needs and synergy, “Who could be the most suitable partner?” For more details, please read our report released on 30th November, 2011 on Onyx pharma titled “M&A Rumors Fuel Investors Interest and Stock Movement”

Contents

COMPANIES MENTIONED

ONYX PHARMA

I would like to order

Product name: Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement

Product link: <https://marketpublishers.com/r/OFE6925F280EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OFE6925F280EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

